Stay updated on Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial
Sign up to get notified when there's something new on the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page.

Latest updates to the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has undergone significant revisions to the description of the BXCL501 Phase Ib trial, including the removal of detailed information about the trial's design, objectives, and inclusion/exclusion criteria, while retaining some key elements of the study's structure.SummaryDifference38%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.SummaryDifference1%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page.